Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 2.99 | 0.65 | 0.93 | 3.10 | 0.58 | 1.81 | — | — | — | 2.92 | 19.73 | 1.75 | — | — | — | — | — | — | — | — | — |
| — | -64.0% | — | — | — | -37.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 91.88 | — | — | — | — | — | 11.03 | — | — | — | — | — | — | 53.42 | 32.77 | 172.23 | 92.88 | 65.91 | 125.59 | 261.44 | 215.60 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | -19.0% | -73.9% | -34.1% | -56.9% | -47.9% | +38.8% | +596.5% | +624.9% | |
| P/B Ratio | 0.95 | 0.64 | 0.60 | 0.61 | 0.56 | 0.62 | 0.63 | 0.66 | 0.64 | 0.61 | 0.73 | 0.57 | 0.71 | 0.96 | 0.58 | 3.10 | 1.65 | 1.16 | 2.06 | 4.13 | 5.06 |
| — | +3.2% | -5.0% | -8.9% | -13.0% | +2.9% | -13.9% | +15.7% | -9.9% | -36.5% | +26.0% | -81.5% | -57.0% | -17.7% | -71.8% | -24.8% | -67.3% | -76.7% | -57.6% | +15.1% | +105.1% | |
| P/FCF | — | — | — | — | — | — | — | — | — | 12.90 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 0.47 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 0.47 | — | 1.93 | 0.26 | 1.54 | — | — | — | 0.51 | 15.92 | 2.35 | — | — | — | — | — | — | — | — | — |
| — | -69.7% | — | — | — | +202.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 0.7% | — | — | — | — | — | 0.7% | — | — | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | -754.4% | — | — | — | — | — | -225.0% | — | — | — | — | — | — | -562.5% | -782.0% | -1430.2% | -1200.7% | -1693.9% | -1689.5% | -1195.8% | -1084.9% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | +66.8% | +53.7% | -19.6% | -10.7% | -88.6% | -130.8% | -38.3% | -144.9% | |
| Net Margin | 3202.5% | — | — | — | — | — | -382.1% | — | — | — | — | — | — | -177.2% | -270.0% | -1254.5% | -1063.5% | -1562.8% | -1565.3% | -1170.6% | -1003.4% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | +88.7% | +82.8% | -7.2% | -6.0% | -104.4% | -125.9% | -41.7% | -128.1% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 37.1% | 28.1% | 17.5% | 5.0% | 27.2% | 9.1% | -5.4% | -6.8% | -11.8% | 5.4% | 0.9% | 8.6% | -2.2% | -0.8% | -1.2% | -5.6% | -4.7% | -6.7% | -6.3% | -5.5% | -7.4% |
| — | +210.6% | +426.5% | +173.5% | +329.9% | +68.0% | -673.2% | -179.0% | -448.7% | +778.8% | +178.3% | +252.7% | +54.5% | +88.1% | +80.9% | -2.2% | +35.8% | +23.9% | +47.2% | +69.9% | +17.5% | |
| ROA | 33.2% | 24.5% | 15.3% | 4.4% | 25.3% | 8.6% | -5.0% | -6.4% | -11.2% | 4.8% | 0.7% | 5.9% | -1.7% | -0.8% | -1.1% | -5.2% | -4.4% | -6.3% | -5.9% | -5.1% | -6.6% |
| — | +184.9% | +403.8% | +169.7% | +325.5% | +80.9% | -796.9% | -207.7% | -575.0% | +728.7% | +164.7% | +212.8% | +62.5% | +88.0% | +81.0% | -3.1% | +32.5% | +14.0% | +34.5% | +60.9% | +0.4% | |
| ROIC | -9.2% | -0.8% | -1.4% | -2.8% | -1.3% | -1.8% | -4.3% | -2.6% | -2.3% | -1.7% | -1.2% | -1.4% | -1.2% | -2.1% | -3.3% | -6.3% | -5.0% | -6.6% | -6.1% | -6.7% | -21.3% |
| — | +57.1% | +66.5% | -5.9% | +44.2% | -5.5% | -272.8% | -91.7% | -88.6% | +17.3% | +64.8% | +78.2% | +76.2% | +68.3% | +46.7% | +6.9% | +76.5% | +79.4% | +74.6% | +78.7% | -81.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | 0.32 | 0.51 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| — | -61.1% | +48.4% | +61.4% | +54.1% | +115.2% | -98.9% | -99.2% | -99.5% | -42.6% | +3560.1% | +5258.6% | +8624.5% | -24.7% | -21.4% | +100.3% | +28.5% | -21.1% | -44.5% | -87.0% | +100.5% | |
| Debt / EBITDA | — | 0.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.98 | 4.98 | 6.45 | 6.98 | 22.24 | 26.81 | 23.94 | 25.19 | 27.08 | 41.06 | 5.28 | 3.06 | 2.25 | 141.49 | 31.21 | 27.34 | 24.55 | 21.01 | 22.70 | 19.89 | 14.27 |
| — | -81.4% | -73.0% | -72.3% | -17.8% | -34.7% | +353.6% | +724.6% | +1104.7% | -71.0% | -83.1% | -88.8% | -90.8% | +573.3% | +37.5% | +37.5% | +72.0% | +67.3% | +134.3% | +217.0% | +59.8% | |
| Quick Ratio | 6.98 | 4.98 | 6.45 | 6.98 | 22.24 | 26.81 | 23.94 | 25.19 | 27.08 | 41.06 | 5.28 | 3.06 | 2.25 | 141.49 | 31.21 | 27.34 | 24.55 | 21.01 | 22.70 | 19.89 | 14.27 |
| — | -81.4% | -73.0% | -72.3% | -17.8% | -34.7% | +353.6% | +724.6% | +1104.7% | -71.0% | -83.1% | -88.8% | -90.8% | +573.3% | +37.5% | +37.5% | +72.0% | +67.3% | +134.3% | +217.0% | +59.8% | |
| Interest Coverage | — | — | — | 29.07 | — | — | -1.76 | -0.63 | -0.20 | 42.52 | 3.59 | 11.98 | -3.50 | — | — | — | -7.90 | -32.62 | -20.68 | -46.06 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ORMP stock.
Oramed Pharmaceuticals Inc.'s current P/E is 3.0x. The average P/E over the last 4 quarters is 1.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Oramed Pharmaceuticals Inc.'s current operating margin is -754.4%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Oramed Pharmaceuticals Inc.'s business trajectory between earnings reports.